Compare AdaptHealth Corp (AHCO) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AdaptHealth Corp vs McCormick & Company, Incorporated — how do they compare? AdaptHealth Corp trades at $10.07 (market cap $1.38B), while McCormick & Company, Incorporated trades at $51.83 (market cap $14.04B). The key difference: McCormick & Company, Incorporated is far larger — about 10.2× AdaptHealth Corp's market cap, and McCormick & Company, Incorporated pays a 3.68% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | MKC | |
|---|---|---|
Market Cap | $1.38B | $14.04B |
Sector | Health | Consumer Staples |
52-Week High | $13.38 | $72.90 |
52-Week Low | $8.68 | $45.60 |
Enterprise Value | $3.33B | $18.64B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
McCormick (MKC) trades at $52.22, down 2.3% today but maintains a bullish technical outlook with strong support at $51. The company delivered solid Q2 2026 results with earnings of $0.80 per share beating estimates, driven by 14% constant currency sales growth and margin expansion to 40.2%. Valuation metrics appear attractive with a P/E of 8.62 and P/S of 1.89, while analyst consensus targets $59.67 representing 14% upside potential.
The investment case centers on MKC's defensive positioning in consumer staples, transformative Unilever food business combination potential, and improving profitability. Key risks include soft consumer volume trends in the Americas and execution challenges from the pending acquisition. With 36.7% of analysts rating the stock a buy and institutional ownership stable, MKC offers value with a 4% dividend yield amid ongoing operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
